MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinson’s"

  • 2024 International Congress

    Impact of 24-hour Subcutaneous Levodopa/Carbidopa Infusion (ND0612) on Motor State Transitions Throughout the Day

    A. Ellenbogen, J. Ferreira, F. Stocchi, K. Kieburtz, A. Albanese, L. Adar, N. Vostokova, J. Pereira, R. Hauser (Farmington Hills, USA)

    Objective: Evaluate the effect of investigational ND0612 infusion on the daily number of, duration of, and transitions between PD motor states, as assessed by home…
  • 2024 International Congress

    NouvNeu001, A Phase 1 Stage Chemically Induced Human Dopaminergic Progenitor Cell Therapy for the Treatment of Mid- to Late-stage Parkinson’s Disease

    M. Cai, J. Wei, X. Ren, R. Yan, H. Chen, N. Xiong (Wuhan, China)

    Objective: To access the efficacy and safety of NouvNeu001 in models of Parkinson’s Disease (PD) and a Phase 1 clinical trial (NCT#06167681). Background: Parkinson's disease…
  • 2024 International Congress

    ENLITE PD – A Dose Selection Trial of Light Therapy for Impaired Sleep in Parkinson’s Disease

    A. Videnovic, E. Macklin, C. Coffey, M. Cudkowicz, HJ. Cho, J. Ohayon, A. Amara, K. Marder, P. Zee, C. Desir, H. Ernst, E. Steinhart, M. Costigan, A. Gudjonsdottir, D. Ecklund, M. Chase, S. Criswel, D. Charles, J. Coleman, A. Espay, A. Hung, S. Kadimi, A. Killoran, L. Luo, R. Malkani, J. Margolesky, J. Marsella, C. Maurer, D. Mihaila, P. Moretti, A. Park, P. Phielipp, H. Sarva, B. Shah, H. Shill, A. Siderowf, V. Suski, J. Tate, W. Tse, K. Wyant, L. Zhang, E. Klerman (Boston, USA)

    Objective: To determine if either once or twice-daily bright white light therapy (BWLT) improves sleep sufficiently relative to two control LT conditions to warrant proceeding…
  • 2024 International Congress

    Lithium Therapy Associated with Reductions in Serum Neurofilament Light Chain (NfL) in Parkinson’s Disease.

    T. Guttuso, JR., R. Shepherd (Williamsville, USA)

    Objective: To assess the effects of lithium aspartate and lithium carbonate therapy for 24 weeks on serum NfL in Parkinson’s disease (PD). Background: Lithium has…
  • 2024 International Congress

    The Effects of Baduanjin on Fine Motor Skills in Mild and Moderate Parkinson’s Disease

    JUN. Li, KF. Li, HZ. Chen, WM. Yang (Hefei, China)

    Objective: To investigate whether Baduanjin Qigong exercise could help improve fine motor skills in patients with Parkinson's disease. Background: It is common for people with…
  • 2024 International Congress

    Neuroprotective Action of Betulin in Parkinson’s disease: Alleviating Mitochondrial Dysfunction and Oxidative Stress-Induced Apoptosis in rat model

    A. Kumar (Allahabad, India)

    Objective: The objective of this study was to evaluate the neuroprotective efficacy of Betulin in MPTP-induced mice models of Parkinson's disease (PD), focusing on its…
  • 2024 International Congress

    Beta peaks as predictor for DBS outcome in Parkinson’s disease

    V. Molinari, M. Sure, E. Florin, C. Hartmann, A. Schnitzler (Düsseldorf, Germany)

    Objective: Determining the relevance of subthalamic (STN) beta peaks in Parkinson's disease (PD) patients with deep brain stimulation (DBS) in relation to the best possible…
  • 2024 International Congress

    Adherence and Persistence Among Patients with Parkinson’s Disease Initiating Istradefylline: 12-Month Follow-Up from US Real-World Data

    R. Joseph, J. Qian, H. Cummings, Y. Chen, S. Tewari, M. Soileau (Columbus, USA)

    Objective: To evaluate 12-month adherence and persistence and identify factors associated with persistence among Parkinson’s disease (PD) patients initiating istradefylline, the first non-dopaminergic adjunct targeting…
  • 2024 International Congress

    Bioreactor-produced iPSCs-derived Dopaminergic Neuron-containing Neural Microtissues Innervate and Restore Motor Function in a Dose-dependent Manner in a Parkinson Rat Model

    N. Prudon, L. Cordero-Espinoza, M. Abarkan, B. Gurchenkov, C. Morel, M. Lepleux, V. de Luca, N. Pujol, L. Milvoy, P. Morand, F. Moncaubeig, H. Wurtz, L. Poinçot, M. Demarco, A. Jonckeau, J. Plétenka, E. Luquet, K. Schmit, L. Piouceau, S. Guilbert, L. Manache-Alberici, M. Lanero, G. Dabee, T. Dufourd, J. Schroeder, K. Alessandri, E. Bezard, E. Faggiani, M. Feyeux (Bordeaux, France)

    Objective: To demonstrate the efficacy of a ready-to-graft 3D neural microtissue product – manufactured at large scale – as a therapeutically viable option to treat Parkinson’s…
  • 2024 International Congress

    Clinical Response and Reduction in Medication Use After Deep Brain Stimulation Surgery in a Cohort of Parkinson’s Disease Patients in Colombia

    T. Lopez Gonzalez, S. Poveda, M. Fonseca, P. Arango, O. Rojas, G. Monsalve, JC. Diez, J. Lobato, O. Bernal Pacheco (Bogotá, Colombia)

    Objective: The objective is to investigate the clinical outcomes and subsequent use of medications in a group of Colombian Patients with DBS Surgery. Background: Parkinson's…
  • « Previous Page
  • 1
  • …
  • 53
  • 54
  • 55
  • 56
  • 57
  • …
  • 338
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Welcome to the MDS Abstracts Site
  • Life expectancy with and without Parkinson’s disease in the general population
  • Nilotinib for treating MSA: A preclinical proof of concept study
    • Welcome to the MDS Abstracts Site
    • Effect of marijuana on Essential Tremor: A case report
    • Advanced Search
    • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Covid vaccine induced parkinsonism and cognitive dysfunction
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley